

Constant Pharma announces Japanese patent issuance

07 March 2018 | News

Previous research has shown that TXA302 improves functional recovery across all endpoints in three different rat models of stroke recovery.



Constant Pharmaceuticals LLC, a privately held US based biopharmaceutical company focused on the treatment of stroke recovery, recently announced that the Japanese Patent Office has issued a patent covering the use of TXA302 in the treatment of stroke. TXA302 is a proprietary analogue of the naturally occurring peptide Angiotensin (1-7).

Previous research has shown that TXA302 improves functional recovery across all endpoints in three different rat models of stroke recovery.

TXA302 is an analogue of Angiotensin (1-7), which is part of an alternative pathway of the renin-angiotensin system. The company's research suggests that TXA302 achieves its effects on angiogenesis and plasticity in the brain by stimulating endothelial progenitor cells and oligodendrocyte progenitor cells, leading to increases in brain-derived neurotrophic factor and other factors.

Constant Pharmaceuticals expects to initiate a Phase 2 clinical trial in stroke recovery in early 2019.